Literature DB >> 14603351

Antiangiogenesis: the fifth cancer treatment modality?

Dawn Camp-Sorrell1.   

Abstract

PURPOSE/
OBJECTIVES: To describe the biologic process of angiogenesis and the potential role of antiangiogenesis therapy in cancer treatment. DATA SOURCES: Published articles, conference proceedings, and computerized databases. DATA SYNTHESIS: Angiogenesis is the development of blood vessels. Antiangiogenic agents prevent the development of blood vessels, therefore preventing one mode of cancer metastasis. Clinical trials must be conducted to ascertain the most powerful antiangiogenic therapies. Trials combine chemotherapy, biotherapy, and radiotherapy with antiangiogenic therapy.
CONCLUSIONS: Information from animal studies has revealed that antiangiogenesis is a viable option in treating cancer and preventing metastasis. Although human studies are rare, preliminary results are promising, especially when antiangiogenesis is used in combination with current cancer treatment modalities. IMPLICATIONS FOR NURSING: Nurses are in a unique position to teach patients about new treatments for cancer. Nurses must be knowledgeable about angiogenesis and the availability of potential antiangiogenesis agents. Nurses will be vital in collecting data in clinical trials, considering the subjective data that will be obtained.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14603351     DOI: 10.1188/03.ONF.934-944

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  3 in total

1.  Effects of recombinant human canstatin protein in the treatment of pancreatic cancer.

Authors:  Xiao-Ping He; Zhao-Shen Li; Ren-Min Zhu; Zhen-Xing Tu; Jun Gao; Xue Pan; Yan-Fang Gong; Jing Jin; Xiao-Hua Man; Hong-Yu Wu; Ai-Fang Xu
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

2.  Inhibitory effect of Bifidobacterium infantis-mediated sKDR prokaryotic expression system on angiogenesis and growth of Lewis lung cancer in mice.

Authors:  Zhao-Jun Li; Hong Zhu; Bu-Yun Ma; Fen Zhao; Shu-Hua Mao; Tai-Guo Liu; Jian-Ping He; Li-Cong Deng; Cheng Yi; Ying Huang
Journal:  BMC Cancer       Date:  2012-04-26       Impact factor: 4.430

3.  Antitumor effect of sFlt-1 gene therapy system mediated by Bifidobacterium Infantis on Lewis lung cancer in mice.

Authors:  H Zhu; Z Li; S Mao; B Ma; S Zhou; L Deng; T Liu; D Cui; Y Zhao; J He; C Yi; Y Huang
Journal:  Cancer Gene Ther       Date:  2011-09-16       Impact factor: 5.987

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.